Abner Herrman & Brock’s TG Therapeutics TGTX Stock Holding History

Abner Herrman & Brock’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-20,000	Closed	-$201K	–	132
2017 Q2	$201K	Buy	+20,000	New	+$224K	0.04%	128

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Abner Herrman & Brock's TGTX Position: Q3 2017 in Review

Abner Herrman & Brock sold out of TG Therapeutics (TGTX) in Q3 2017, closing a stake of 20,000 shares — an estimated $201K sold.

Abner Herrman & Brock first reported a position in TGTX in Q2 2017 and held it in 1 quarter. The position peaked at $201K in Q2 2017. 101 funds tracked by Wall St. Rank hold TGTX as of Q3 2017.

Abner Herrman & Brock reported no remaining TG Therapeutics position as of Q3 2017 after selling out during the quarter.
Abner Herrman & Brock sold 20,000 TG Therapeutics shares in Q3 2017, an estimated $201K.
Abner Herrman & Brock first reported a position in TG Therapeutics in Q2 2017 and held it in 1 quarter.
Abner Herrman & Brock's TG Therapeutics position peaked at $201K in Q2 2017.
101 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2017.

Based on Abner Herrman & Brock's 13F filing for Q3 2017, filed 6 Oct 2017.